Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

External ValidatIon Trial of ASTER Trial

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Länken sparas på Urklipp
Status
Sponsorer
Universitaire Ziekenhuizen Leuven

Nyckelord

Abstrakt

As the use of endoscopic ultrasonography for mediastinal diagnosis and/or staging is widely spread in Belgium, the investigators aimed to determine the number of mediastinoscopies needed to detect one additional mediastinal lymph node invasion during routine clinical practice in the staging of potentially resectable clinical stage III non-small cell lung cancer.

Beskrivning

Background : The observation made by the ASTER investigators might be criticized as all procedures were performed in highly experienced centers. To date, the number of mediastinoscopies needed to detect one additional N2/3 disease in the routine clinical practice of chest physician performing endosonography for mediastinal staging is unknown. The investigators therefore seek to answer whether a negative endosonography should routinely be followed by mediastinoscopy in day to day clinical practice.

Aim : As the use of endoscopic ultrasonography for mediastinal diagnosis and/or staging is widely spread in Belgium, the investigators aimed to determine the number of mediastinoscopies needed to detect one additional mediastinal lymph node invasion during routine clinical practice.

Setting : centers in Belgium with EBUS-TBNA and/or EUS-FNA experience in at least 20 patients agreed to participate and will include their patients.

Design : Prospective national observational multicenter study. All patients with clinical N2/3 disease based on CT and/or PET requiring invasive mediastinal staging will primarily undergo invasive mediastinal staging with endosonography (EBUS +/- EUS). A subsequent cervical mediastinoscopy will be performed in case no mediastinal lymph node involvement was found with endosonography. Local surgeons perform these procedures according to their institutional practice. Thoracotomy with mediastinal lymph node dissection will be the gold standard for invasive mediastinal staging, in case no mediastinal lymph node metastases were found during clinical staging including endosonography and mediastinoscopy.

Patients : The study will include 255 patients, based on the calculation of 15 consecutive patients in each participating center, in order to validate the ASTER data.

Primary endpoint : The number of mediastinoscopies needed to detect one additional N2/3.

Secondary endpoints : The number of mediastinal lymph nodes stations sampled with endosonography ; the median size of largest mediastinal lymph node sampled; characteristics of mediastinal nodal disease missed by endosonography.

Datum

Senast verifierad: 03/31/2011
Först skickat: 04/04/2011
Beräknad anmälan inlämnad: 04/07/2011
Först publicerad: 04/10/2011
Senaste uppdatering skickad: 10/17/2011
Senaste uppdatering publicerad: 10/18/2011
Faktiskt startdatum för studien: 03/31/2011
Uppskattat primärt slutdatum: 03/31/2013
Beräknat slutfört datum: 06/30/2013

Tillstånd eller sjukdom

Stage III Lung Cancer

Intervention / behandling

Procedure: Endosonography

Fas

-

Armgrupper

ÄrmIntervention / behandling
Experimental: Endosonography
Endoscopic ultrasonography (EBUS-TBNA +/- EUS-FNA) for invasive mediastinal nodal staging
Procedure: Endosonography
in order to stage the mediastinum

Urvalskriterier

Åldrar berättigade till studier 18 Years Till 18 Years
Kön som är berättigade till studierAll
Accepterar friska volontärerJa
Kriterier

Inclusion Criteria:

- Consecutive patients with (suspected) NSCLC in whom invasive mediastinal staging is required based on presence of ACCP group B mediastinal lymph nodes and/or FDG-PET positive (visual interpretation of FDG uptake in mediastinal nodes as present) mediastinal lymph nodes (either ACCP group B or ACCP group D) in lymph node stations 2, 4, 7, 8 or 9 (see Appendix).

- Potentially operable and resectable disease.

- Radically treated previous extrathoracic malignancies are allowed whenever the extrathoracic malignancy is considered in remission, and a primary parenchymal lung tumour is present.

- Provision of a written informed consent.

Exclusion Criteria:

- Previous cervical mediastinoscopy.

- Uncorrected coagulopathy.

- Former treatment for a lung cancer.

- Patient unable to give a written informed consent.

- Absence of a primary parenchymal lung tumour.

- Distant metastases (cM1 disease) after routine clinical work-up.

- Clinical N2/3 disease only based on suspected mediastinal lymph nodes in stations 5 or 6.

- Patients belonging to ACCP groups A and C based on CT scan.

Resultat

Primära resultatåtgärder

1. The number of mediastinoscopies needed to detect one additional N2/3 [1 month]

Efficacy

Sekundära resultatåtgärder

1. The number of mediastinal lymph nodes stations sampled with endosonography [1 month]

Characteristics of nodal staging; the median size of largest mediastinal lymph node sampled; characteristics of mediastinal nodal disease missed by endosonography.

Gå med på vår
facebook-sida

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

  • Fungerar på 55 språk
  • Växtbaserade botemedel som stöds av vetenskap
  • Örter igenkänning av bild
  • Interaktiv GPS-karta - märka örter på plats (kommer snart)
  • Läs vetenskapliga publikationer relaterade till din sökning
  • Sök efter medicinska örter efter deras effekter
  • Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning

Google Play badgeApp Store badge